FDA adds heart risk warning to popular antibiotic Zithromax

The Food and Drug Administration is warning doctors and patients that a widely used antibiotic from Pfizer can cause rare but deadly heart rhythms in some patients.

The agency is adding new warnings to the label of Zithromax, which is commonly used to treat bronchitis, pneumonia and other infections.

Doctors should consider prescribing other antibiotics to patients at risk of heart problems, including those with or low levels of potassium or magnesium in their blood.

Zithromax is more expensive than other antibiotics, but it's popular because it often can be taken for fewer days.

The FDA warning could convince doctors to choose other options for people prone to heart problems, though the new label notes that some other antibiotics have similar effects on the heart.

0 shares

Related Stories

FDA adds more warnings to antidepressant's label

date Mar 28, 2012

(HealthDay) -- In a follow-up to a warning that high doses of the popular antidepressant Celexa can cause potentially fatal abnormal heart rhythms, the U.S. Food and Drug Administration has issued new dosing ...

FDA adds heart warning to Pfizer anti-smoking pill

date Jun 16, 2011

(AP) -- Federal health regulators are warning doctors and patients that Pfizer's anti-smoking drug Chantix may slightly increase the risk of heart attack and other cardiovascular problems.

FDA adds new heart warning to Sanofi's Multaq

date Dec 19, 2011

Federal health officials have added new safety warnings to the heart rhythm drug Multaq after company studies linked the pill to higher rates of heart attack, stroke and death in a subset of patients.

Recommended for you

Teva to lift bid for Mylan: report

date 11 hours ago

Israeli pharmaceutical giant Teva plans to increase its bid for rival Mylan and could announce the move as soon as this week, according to a US media report Monday.

Vaccine for West Nile Virus enters human clinical trials

date 16 hours ago

A clinical trial of a new investigational vaccine designed to protect against West Nile Virus infection will be sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes ...

FDA clears drug for leading form of cystic fibrosis

date Jul 02, 2015

Federal health officials have approved a new combination drug for the most common form of cystic fibrosis, the debilitating inherited disease that causes internal mucus buildup, lung infections and early death. But it will ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.